CLEO Confirms Next-Gen Platform for Ovarian Cancer Test
Filed with ASX · · 3 pages · English
▪ Both parties aligned to enter long-term manufacturing supply agreement following completion of these activities. The Ella™ platform is an automated enzyme-linked immunosorbent assay (ELISA) platform designed to deliver accurate, reproducible data with reduced manual input. Using CLEO’s test kit, patient blood samples are processed in a laboratory on the Ella™ platform. The platform uses microflu
Story so far
Earlier from CLEO Diagnostics
- Quarterly activities and cashflow report
- CLEO Raises $5m to Support U.S. Market Launch
- Trading Halt
- Cleo Strengthens Cash Position with $1.7m R&D Tax Refund
- CLEO Appoints First Key Opinion Leader to Support US Market
Later from CLEO Diagnostics
- Appendix 4D and Half Yearly Accounts
- CLEO Optimises Biomarker Panel Ahead of FDA Submission
- Sample Collection Completion for Pivotal US Clinical Trial
- CLEO Commences Kit Manufacturing Ahead of FDA Submission
- CLEO Establishes U.S. Reimbursement Pathway
Follow CLEO Diagnostics into a list and get an email when it puts out news.
Follow CLEO Diagnostics